Roth Capital analyst Kumaraguru Raja resumed coverage of Dare Bioscience (DARE) with a Buy rating and $5 price target. The analyst notes that XACIATO for treatment of bacterial vaginosis is licensed to Organon for commercialization following FDA approval; Sildenafil Cream for female sexual arousal disorder and Ovaprene for contraception are in advanced stages of clinical development; and Dare has a license agreement with Bayer (BAYRY) for the commercialization of Ovaprene in the U.S. Raja believes that the risk-reward is favorable and clinical success would enhance interest in the company.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DARE:
- Dare Bioscience price target raised to $7 from $6 at H.C. Wainwright
- Dare Bioscience announces new DARE-PDM1 development program
- Dare Bioscience initiated with a Buy at JonesTrading
- Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
- Daré Bioscience to Present at the Stifel 2022 Healthcare Conference